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Abstract
Background: In China, high-risk human papillomavirus (HR-HPV) prevalence is unexpectedly high in older women,
but the possible reasons have not been well studied yet. This study investigated the age trends of HR-HPV infection
in a prospective study.
Methods: A total of 7397 women aged 25-65 years without cervical precancer or cancer were evaluated during
2010-2011 with a stratified sample of 2791 women re-evaluated after one year. Test results for careHPV and
careHPV16/18/45 were used to describe the HR-HPV prevalence, incidence and clearance. Risk factors associated
with HR-HPV infections were explored using a logistic regression model.
Results: The overall HR-HPV prevalence was 13.1% at baseline, with a peak of 19.3% in women aged 55-59 years.
The prevalence of HR-HPV (p for trends < 0.001), HPV16/18/45 (p for trends = 0.002), and HR-HPV other than HPV16/
18/45 (p for trends = 0.002) generally increased with increasing age. Number of infections that cleared was generally
greater than number of incident infections within age groups. One-year clearance rate decreased with increasing
age (p for trends < 0.001), however, incidence rate was unrelated to age (p for trends = 0.159). Risk factors that
associated with HR-HPV infection differed between younger and older women.
Conclusions: The greater HR-HPV prevalence in older versus younger women in rural China may be explained by a
cohort effect, higher than expected incidence, and/or poorer clearance at older age.
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Background
Previous studies of age-specific high-risk human papilloma-
virus (HR-HPV) prevalence have demonstrated substantial
variability across geographical regions [1-3]. Typically,
women within a few years of their age of sexual debut were
observed to have the highest HR-HPV prevalence. A
second peak of HR-HPV prevalence around the age of
menopause has been observed in some populations [4,5],
while absent in others [6,7].
Due to the lack of well-organized, nation-wide HPV-
based cervical cancer screening programmes, the age dis-
tribution of HPV prevalence in China has not been well
demonstrated, and results from population-based studies
also differed from each other [8-12]. More recently, a
pooled analysis reported a pronounced increase of HR-
HPV prevalence in women around the age of menopause
in rural China [13]. However, almost all mentioned studies
were cross-sectional in nature (i.e., no longitudinal follow-
up), limiting the interpretation of age-specific HR-HPV
prevalence in China.
In particular, persistent infection with HR-HPV is the
necessary cause of cervical cancer and its precancerous le-
sions such as cervical intraepithelial neoplasia grade 2 or 3
(CIN2/3) [14-16]. One-year HR-HPV persistence strongly
predicts which infection will continue to persist [17] and
progress to CIN2/3 [18]. In the U.S., evidence of one-year
HR-HPV persistence results in referral to colposcopy [19].
World Health Organization (WHO) is now considering 6-
month persistent infection as a surrogate endpoint for
HPV vaccine trials.
We therefore wanted to further characterize the age-
specific patterns of HR-HPV infections in rural China.
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Using data from a multi-center study of lower-cost molecu-
lar HPV tests in rural China, we described the prevalence
and short-term (one-year) dynamics of HR-HPV infection
as measured by careHPV (Qiagen, Gaithersburg, MD,
USA), a DNA test for a pool of 13 carcinogenic HPV geno-
types and one possible carcinogenic HPV genotype, which
had been evaluated in multiple countries [20,21], and a
research-use only DNA test for a pool of HPV16,18, and 45
(HPV16/18/45) made available for the careHPV platform
(“careHPV16/18/45”). We also investigated risk factors for
prevalence, incidence, and one-year clearance of HR-HPV.
Methods
Study population and procedures
A total of 7541 women aged 25- to 65-year living in rural
villages in Shanxi, Henan and Jiangxi provinces were en-
rolled from October 2010 to August 2011 in a study called
“Screening Technologies to Advance Rapid Testing for
Cervical Cancer Prevention–Utility and Program Planning
(START-UP)” Project. Participant recruitment processes
and study procedures were described elsewhere [22].
Briefly, women were considered to be eligible if they: 1)
had not been previously diagnosed with cervical cancer; 2)
had a cervix; 3) were not pregnant; 4) were physically able
to undergo routine cervical cancer screening; and 5) were
able to provide informed consent. Each participant pro-
vided a written informed consent and a staff-administered
questionnaire survey was conducted in a private room. Six
screening tests were performed on each participant, in-
cluding OncoE6™ (Arbor Vita Corporation, Fremont, CA,
USA), careHPV and Hybrid Capture 2 (HC2) (QIAGEN,
Gaithersburg, MD, USA) tested on both self- and
clinician-collected specimens and visual inspection with
acetic acid (VIA). Woman who were tested positive by
any of the six tests or tested negative by all six tests but
was selected as a part of ~10% random sample underwent
a rigorous colposcopic evaluation using a biopsy protocol
as previously described [23]. The primary histological
diagnoses were done by two pathologists in CICAMS until
reaching an agreement. A U.S. pathologist independently
reviewed each initial biopsy or surgical specimen diag-
nosed as CIN2+, and any discordant diagnoses were set-
tled from discussions with the Chinese pathologists [22].
One hundred and forty four women with histology con-
firmed CIN2+ at baseline were excluded with 7397
women in this analysis. Of the 2147 screen-positive
women, 1859 (86.6%) returned for one-year follow-up; of
the 5250 screen-negative women, 1014 were randomly se-
lected for one-year follow-up, of whom, 932 (91.9%)
returned in a year (Figure 1). All follow-up procedures
Figure 1 Flowchart of inclusion and exclusion of the study participants. At baseline, 144 women were excluded because of biopsy
confirmed CIN2+, with 7397 women in the baseline analysis. 288 of the 2147 baseline screen positives were lost to follow-up and 82 of the 1014
randomly selected baseline screen negatives were lost to follow-up, which added up to 2791 women in the follow-up analysis. CIN2+:cervical
intraepithelial neoplasia grade 2 or above.
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were the same as the baseline screening without any
questionnaire survey.
This study is part of the START-UP Project which was
approved by the PATH and Cancer Institute and Hospital,
Chinese Academy of Medical Sciences (CICAMS) institu-
tional review boards (IRBs).
HPV DNA testing
careHPV was used to detect HPV DNA in both self-
and clinician-collected specimens. careHPV is a CE
Marked and Chinese Food and Drug (CFDA)-approved
signal-amplification DNA assay that uses antibody cap-
ture of HPV DNA and RNA probe hybrids with chemi-
luminescent signal detection. Same as HC2 [24], the
relative light unit/cutoff ratio (RLU/CO) is provided as a
semi-quantitative measurement of HPV viral load. All
careHPV-positive specimens were also tested periodic-
ally in a batch-wise fashion for HPV16, 18, and 45 by
careHPV16/18/45.
Statistical analysis
The prevalence of overall HR-HPV and HPV16/18/45
were demonstrated directly by careHPV and careHPV16/
18/45 results, while the prevalence of HR-HPV other than
HPV16/18/45 (other HR-HPV) was inferred as careHPV-
positive but careHPV16/18/45-negative.
The overall HR-HPV prevalence at baseline was stan-
dardized by using the world standard population that was
reported by the WHO in 2001 [25]. Age-specific preva-
lence of overall HR-HPV, HPV16/18/45 and other HR-
HPV at baseline were simply presented by numbers and
rates. Cochran-Armitage trend test was used to test the
age trends. Univariate and multivariate logistic regression
models were used to calculate the crude and adjusted
odds ratios (ORs) of risk factors with 95% confidence in-
tervals (CIs) presented by Wald ϰ2 statistics. The HPV sta-
tus in the successive visits were used to demonstrate
incidence (-/+) and clearance (+/-). The number of inci-
dence was adjusted for approximately 20% sampling frac-
tion of baseline screen-negative women. McNemar’s ϰ2
test was used to compare the estimated number of inci-
dence and clearance. The adjusted prevalence at follow-up
was determined by the estimated number of incidence
and clearance.
The results were confirmed by using HC2 outcomes
(data not shown). To increase the analytic sensitivity,
these analyses were redone by combining the careHPV
and HC2 results (i.e., HPV positive was defined by either
careHPV positive or HC2 positive).
SPSS 17.0 (SPSS Inc., Chicago, USA) was used to
analyze the data. Statistical significance was assessed by
two-tailed tests with an α level of 0.05.
Results
The median, mean, and age range of the participants were
44, 44.5, and 25-65 years, respectively; 27.5% of the partic-
ipants were menopausal at baseline, and the mean age at
menopause was 48.7 years. Most women were Han ethni-
city (99.9%), farmers (75.5%), currently married (97.1%),
and of less than 12 years’ education (98.2%). Most women
reported that they did not smoke (99.6%) or drink alcohol
(91.5%). Most women have self-reported only one sexual
partner in their lifetime (87.3%).
Overall, 969 of 7397 women (13.1%, 95% CI: 12.3%-
13.9%) were HR-HPV positive at baseline, and the positive
rates varied among study sites (12.8% for Yangcheng,
11.9% for Xinmi, and 15.4% for Tonggu). The prevalence
of HR-HPV age-standardized to the world’s standard
population was 14.2% (95% CI: 13.4%-15.0%). The crude
prevalence of HPV16/18/45 was 2.9% (22.3% of all HR-
HPV) and of other HR-HPV was 10.2%.
Risk factors associated with the HR-HPV infection are de-
scribed in Table 1. Univariate analysis showed that age,
household income, marital status, age at first menstruation
period, age at first sexual intercourse, number of lifetime sex
partners, number of sex partners in the past 6 months, age
at first pregnancy, number of live births, and menopausal
status were significantly associated with HR-HPV infection.
In the multivariate model that was adjusted for study sites,
education levels and oral contraceptive history, women who
were not currently married (OR= 1.50, 95% CI: 1.07-2.12),
younger at sex initiation (≤19 vs. ≥23, OR = 1.23, 95% CI:
1.00-1.51), had more than one lifetime sex partners
(OR = 1.30, 95% CI: 1.07-1.58), and postmenopause
(OR = 1.47, 95% CI: 1.26-1.71) were significantly more
likely to have HR-HPV infections. Number of sex partners
in the past 6 months was not found to be the independent
risk factor for HR-HPV infections (Multivariate analysis:
p = 0.086).
Risk factors associated with HR-HPV infections have
also been stratified by tertiles of age (i.e., 25-40, 41-48 and
49-65 years), with the prevalence of 11.4%, 12.4%, and
15.8%, respectively (Table 2). Household income, marital
status, age at first menstruation period and age at first
pregnancy were found to be associated with HR-HPV in-
fection in women aged 25-40 years. By comparison, age at
first intercourse showed significant association in 41 to
48-year-old women; and lifetime number of sex partners
and menopausal status were significantly associated with
having HR-HPV in women aged 49-65 years.
Figure 2 illustrates the age-specific prevalence of overall
HR-HPV, HPV16/18/45 and other HR-HPV at baseline by
5-year intervals. The age-specific prevalence of overall HR-
HPV between 25 and 54 years formed a “U-shaped curve”,
with a prevalence of 13.2% in women aged 25-29 years and
13.9% in women aged 50-54 years and a nadir of 10.9% in
women aged 30-34 years. The prevalence peaked in the
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55-59 year age group at 19.2% and then decreased to
14.6% in the 60-65 year age group. A similar age pattern
was observed for other HR-HPV. In contrast, the preva-
lence of HPV16/18/45 appeared to rise steadily with age
p for trend = 0.002) but there was no spike in the preva-
lence in the 55-59 year age group. The HR-HPV preva-
lence performed on the definition of either careHPV
positive or HC2 positive showed similar age trends.
The average follow-up time of the stratified sample of
women was 11.7 (SD = 0.3) months. The crude and sam-
pling fraction-adjusted HR-HPV prevalence at follow-up
was 20.6% and 11.1%, respectively. The net change in
HR-HPV infection is demonstrated in Table 3. The total
and age-specific numbers of new HPV infection were less
than those of HPV clearance, except for women aged 35-
39 and 60-65 years, although most of the differences were
not statistically significant.
The age trends of incidence and clearance of overall HR-
HPV, HPV16/18/45 and other HR-HPV are illustrated in
Figure 3. The clearance of overall HPV, HPV16/18/45 and
other HPV declined with increasing age (p for trends < 0.05,
for all), while no significant trends for incidence of overall
HR-HPV, HPV16/18/45 and other HR-HPV were observed
(p for trends > 0.05, for all). The HR-HPV incidence
and clearance rates performed on the definition of either
careHPV positive or HC2 positive showed similar results.
The baseline risk factors of HR-HPV incidence and
clearance are also investigated (Table 4). Women who had
more than one sex partners in the last 6 months were
more likely to have an incident HR-HPV infection at the
one-year follow-up (2 vs. 0, OR = 7.80, 95% CI: 2.46-
24.75), while older women and women with higher base-
line HR-HPV signal strength, a semi-quantitative measure
of HR-HPV viral load [26,27], were less likely to clear the
infection. Infection of HPV16/18/45 was marginally asso-
ciated (p = 0.052, OR = 0.70, 95% CI: 0.48-1.00) with less
clearance compared to other HR-HPV genotypes.
Discussion
This study investigated the age-specific prevalence of
overall HR-HPV, HPV16/18/45 and other HR-HPV in 25
to 65-year-old women without cervical precancer and can-
cer in a prospective study in rural China. It focused on the
Table 1 Risk factors associated with overall HPV infection
at baseline




Age p < 0.001
25-29 326 (4.4) 43 (13.2) 1.0
30-34 631 (8.5) 69 (10.9) 0.81 (0.54-1.21)
35-39 1330 (18.0) 153 (11.5) 0.86 (0.60-1.23)
40-44 1555 (21.0) 188 (12.1) 0.91 (0.64-1.29)
45-49 1425 (19.3) 172 (12.1) 0.90 (0.63-1.29)
50-54 906 (12.2) 126 (13.9) 1.06 (0.73-1.54)
55-59 846 (11.4) 163 (19.3) 1.57 (1.09-2.26)
60-65 378 (5.1) 55 (14.6) 1.12 (0.73-1.72)
Household income (Yuan)§ p = 0.044
≤3000 2609 (35.4) 373 (14.3) 1.0
3001-5000 2254 (30.6) 268 (11.9) 0.81 (0.68-0.96)
≥5001 2502 (34.0) 323 (12.9) 0.89 (0.76-1.04)
Marital status p < 0.001*
Married 7180 (97.1) 920 (12.8) 1.0
Others 217 (2.9) 49 (22.6) 1.99 (1.43-2.75)
Age at first menstruation period (years)§ p = 0.007
≤14 2654 (35.9) 323 (12.2) 1.0
15-16 2686 (36.4) 336 (12.5) 1.03 (0.88-1.22)
≥17 2047 (27.7) 309 (15.1) 1.28 (1.09-1.52)
Age at first sexual intercourse (years)§ p < 0.001*
≤19 1499 (20.3) 252 (16.8) 1.0
20-22 4022 (54.4) 487 (12.1) 0.68 (0.58-0.80)
≥23 1874 (25.3) 230 (12.3) 0.69 (0.57-0.84)
No. of lifetime sex partners§ p = 0.001*
1 6460 (87.3) 815 (12.6) 1.0
≥2 936 (12.7) 154 (16.5) 1.36 (1.13-1.65)
No. of sex partners in the past 6 months p = 0.006
0 763 (10.3) 121 (15.9) 1.0
1 6553 (88.6) 831 (12.7) 0.77 (0.63-0.95)
≥2 81 (1.1) 17 (21.0) 1.41 (0.79-2.50)
Age at first pregnancy (years)§ p = 0.001
≤20 1954 (26.6) 302 (15.5) 1.0
21-23 3553 (48.4) 427 (12.0) 0.75 (0.64-0.88)
≥24 1834 (25.0) 227 (12.4) 0.77 (0.64-0.93)
No. of live births§ p < 0.001
0-2 5438 (73.5) 661 (12.2) 1.0
≥3 1958 (26.5) 307 (15.7) 1.34 (1.16-1.56)
Table 1 Risk factors associated with overall HPV infection
at baseline (Continued)
Menopausal status§ p < 0.001*
No 5363 (72.5) 629 (11.7) 1.0
Yes 2033 (27.5) 339 (16.7) 1.51 (1.31-1.74)
NOTE: *Risk factors of statistical significance in multivariate analysis which was
adjusted for study sites, education levels and oral contraceptive history.
§Missing values were excluded in the analysis. Bold type indicates statistical
significance (p < 0.05). HPV = human papillomavirus; OR = odds ratio;
CI = confidence interval.
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interpretation for the peak observed in older women.
Moreover, we explored the risk factors of HPV incidence
and clearance using one-year follow-up data.
The age-standardized prevalence by world population of
HR-HPV tested by careHPV at baseline in our study was
14.2%, which was comparable to other studies in mainland
China [8-10], and other parts of Asia/Australia (~15%)
[28]. However, it was lower than a pooled analysis from
China (16.8%) [13]. We reported a prevalence of 2.9% for
HPV16 and/or 18 and/or 45 types, which was lower than
other studies in China [9,10]. These differences are likely
caused by different HPV DNA tests and different study
populations, such as different geographic areas, different
age groups, and different distributions of cervical lesions.
We found that the prevalence as measured by careHPV
was similar to the prevalence as measured by HC2 in our
study (p = 0.196), which suggested that the difference be-
tween the prevalence in this study and the recent pooled
analysis [13] was primarily due to the differences among
study populations.
Previous studies in China had observed a second peak of
HPV prevalence in older women, although the peak age
varied between studies [8-10,13]. In our study, HR-HPV
prevalence peaked at 55-59 years, but lacked the “first
peak” in younger women. It has been well acknowledged
that cumulative risks of 40-50% of HPV acquisition hap-
pened within 2 to 3 years of sexual debut [29-32]. Since
the average age at first sexual intercourse of our study par-
ticipants was 21.2 years, the theoretical peak of HPV preva-
lence should appear in women aged 23-24 years. In
addition, Chinese women were less likely to report their
premarital and extramarital sexual histories. In that case,
we hypothesize that the actually age of sexual initiation
may be even younger. However, we only enrolled women
aged over 25 years, therefore we have no chance to see the
“first peak” as observed in other studies [13]. The one-year
Table 2 Risk factors associated with overall HR-HPV infection at baseline by age group




25-40 (n = 2587) Household income (Yuan)§ p = 0.023
≤3000 91 (11.2) 1.0
3001-5000 79 (10.1) 0.96 (0.69-1.34)
≥5001 125 (12.7) 1.41 (1.04-1.92)
Marital status p = 0.007
Married 289 (11.3) 1.0
Others 7 (29.2) 3.48 (1.40-8.66)
Age at first menstruation period (years)§ p = 0.027
≤14 140 (10.5) 1.0
15-16 110 (11.6) 1.06 (0.80-1.40)
≥17 46 (15.3) 1.65 (1.14-2.40)
Age at first pregnancy (years)§ p = 0.004
≤20 97 (14.5) 1.0
21-23 136 (11.0) 0.77 (0.57-1.03)
≥24 55 (8.5) 0.54 (0.38-0.78)
41-48 (n = 2530) Age at first sexual intercourse (years)§ p < 0.001
≤19 74 (21.1) 1.0
20-22 173 (10.9) 0.49 (0.35-0.67)
≥23 66 (11.2) 0.52 (0.36-0.77)
49-65 (n = 2280) No. of lifetime sex partners§ p = 0.006
1 306 (15.0) 1.0
≥2 54 (22.0) 1.58 (1.14-2.20)
Menopausal status§ p = 0.008
No 48 (11.3) 1.0
Yes 311 (16.8) 1.55 (1.12-2.15)
NOTE: *Only those risk factors of statistical significance in multivariate analysis which was adjusted for study sites, education level, oral contraceptive history,
number of sex partners in the past 6 months, number of live births were shown. Age was categorized by tertiles at baseline. Bold type indicates statistical
significance (p < 0.05).§Missing values were excluded in the analysis. HPV = human papillomavirus; OR = odds ratio; CI = confidence interval.
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prospective data demonstrated a larger number of infec-
tions that were cleared versus acquired, which indicated
that HR-HPV prevalence should decrease with progressing
of age, rather than a peak occurred in older women.
The probable explanations for this HR-HPV peak in older
Chinese women could be a cohort effect that leads to in-
creased lifetime exposures, increased HPV incidence ,and/
or increased viral persistence in older women [33] versus
younger women. We considered each as described below.
Cohort effects
Before the one-child policy which had been strictly imple-
mented in year 1979 [34], most women got married at an
early age and gave a large number of births. Risk factor
analysis in our study also found an earlier age at first sex-
ual intercourse and a greater number of live births in 49
to 65-year-old women (data not shown), which may have
led to a higher cumulative exposure to HR-HPV. And in
some high-quality cancer registries in China, a declining
trend in cervical cancer incidence from 1970’s to 1990’s
has been observed [35]. This may partly reflect a higher
HR-HPV burden in older generations (vs. younger genera-
tions according to a report from Sharma et al. [36], which
found a positive association between age-standardized
HPV prevalence and its square-root age-standardized cer-
vical incidence).
However, one-year follow-up was not sufficient to pro-
vide a strong evidence to explain the cohort effect. Long-
term follow-up studies with birth cohort analysis are
needed to further clarify this effect. With recent changes
in sexual norms, we anticipate an upturn in the annual in-
cidence of cervical cancer in China unless widespread sec-
ondary prevention through screening, diagnosis, and
treatment of precancerous lesions is implemented.
Table 3 Incidence, clearance and prevalence of overall HR-HPV infections at one-year follow-up by age
Age group Crude prevalence, n/N (%) Adjusted prevalence, n/N (%) Adjusted incidence, n/N (%) Clearance, n/N (%) Pa
25-29 15/102 (14.7) 28/302 (9.3) 21/269 (7.8) 26/33 (78.8) 0.560
30-34 35/242 (14.5) 51/598 (8.5) 24/541 (4.4) 30/57 (52.6) 0.497
35-39 91/494 (18.4) 141/1 275 (11.1) 82/1 145 (7.2) 71/130 (54.6) 0.419
40-44 100/593 (16.9) 163/1 503 (10.8) 105/1 339 (7.8) 106/164 (64.6) 1.000
45-49 97/552 (17.6) 125/1 390 (9.0) 57/1 235 (4.6) 87/155 (56.1) 0.015
50-54 91/345 (26.4) 108/877 (12.3) 43/765 (5.6) 47/112 (42.0) 0.752
55-59 100/315 (31.7) 116/801 (14.5) 33/667 (4.9) 51/134 (38.1) 0.063
60-65 46/148 (31.1) 56/363 (15.4) 22/316 (7.0) 13/47 (27.7) 0.175
Total 575/2 791 (20.6) 788/7 109 (11.1) 387/6 277 (6.2) 431/832 (51.8) 0.133
NOTE: Since only a portion of baseline screen negative women were followed up at one-year, incidence was adjusted for the sampling fraction. It was calculated as follows:
((1/sampling fraction) * (Number of baseline screen negatives who tested careHPV-positive at follow-up) + (Number of baseline screen positives with careHPV-negative
who tested careHPV-positive at follow-up)) / ((Number of baseline screen negatives) + (Number of baseline screen positives with careHPV-negative who were followed up)).
The clearance was simply calculated by: (Number of cleared) / (Number of baseline careHPV-positive who were followed up). The adjusted prevalence at follow up was
determined as: ((Number of baseline careHPV-positives who were not cleared) + (Number of incidence)) / Total population. Age groups were defined on the basis of age at
baseline. a: the McNemar x2 test is used to test for statistical differences in clearance and incidence; bold type indicates statistical significance (p< 0.05).
Figure 2 Age group-specific prevalence of any high-risk HPV, any HPV16, 18, and/or 45 (HPV16/18/45), and high-risk HPV other than
HPV16/18/45 at baseline. Figure 2 Symbols: (bold line) Overall, (dash line) HPV16/18/45, (dot-dash line with solid diamond) Other.
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HPV incidence
We expected to see a decreased trend in the incidence of
HR-HPV infection in older women as reported in other
studies [33,37], but only observed an independent relation.
This unexpected higher incidence in older women may be
caused by: 1) new HPV infections acquired by changes in
sexual behaviors by either the women or their partners; 2)
reactivation of latent HPV infection due to immune senes-
cence [38,39]. No evidence supported the changes in sex-
ual behaviors in older women although that does not rule
Figure 3 Incidence and clearance of HPV by age group. Incidence is adjusted for sampling fraction of baseline screen negatives. Age groups are
defined on the basis of age at baseline. a. Incidence and clearance of overall HPV infection. b. Incidence and clearance of HPV16/18/45 infection.
c. Incidence and clearance of other HPV infection. Figure 3 Symbols: (gray line with solid triangle) incidence, (black line with solid diamond) clearance.
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Table 4 Risk factors associated with overall HR-HPV incidence and clearance
Incidence/Clearance Risk factors* Univariate Multivariate
OR (95% CI) OR (95% CI)ξ
Incidence (n = 1959) No. of sex partners in the past 6 months p = 0.002 p = 0.001
0 1.0 1.0
1 1.01 (0.58-1.76) 1.11 (0.62-1.97)
2 6.40 (2.04-20.05) 7.80 (2.46-24.75)
Clearance (n = 832) Age (years) p < 0.001 p < 0.001
25-29 1.0 1.0
30-34 0.30 (0.11-0.80) 0.28 (0.10-0.78)
35-39 0.32 (0.13-0.80) 0.36 (0.14-0.91)
40-44 0.49 (0.20-1.20) 0.48 (0.19-1.21)
45-49 0.34 (0.14-0.84) 0.35 (0.14-0.89)
50-54 0.20 (0.08-0.49) 0.19 (0.07-0.48)
55-59 0.17 (0.07-0.41) 0.15 (0.06-0.38)
60-65 0.10 (0.04-0.30) 0.11 (0.04-0.33)












Menopausal status§ p < 0.001 p = 0.433
No 1.0
Yes 0.41 (0.31-0.55)
No. of live births§ p < 0.001 p = 0.695
0-2 1.0
≥3 0.57 (0.42-0.76)
Signal strength (RLU/CO) p < 0.001 p < 0.001
1.00-9.99 1.0 1.0
10.00-99.99 0.27 (0.20-0.38) 0.28 (0.20-0.40)
≥100.00 0.43 (0.29-0.62) 0.40 (0.27-0.59)
HPV16/18/45 p < 0.001 p = 0.052
Negative 1.0 1.0
Positive 0.56 (0.40-0.78) 0.70 (0.48-1.00)
NOTE: *Risk factors were defined on the basis of risk factors at baseline. ξMultivariate logistic model was adjusted for study sites, household income, marital status
and oral contraceptive for incidence and clearance. Furthermore, for incidence, VIA and HC2 results at baseline were also adjusted in the multivariate analysis.
HPV16/18/45 was put into the model for marginally association. In the multivariate analysis, OR was given only if statistical significant. §Missing values were
excluded in the analysis. Bold type indicated statistical significant (p < 0.05). HPV = human papillomavirus; OR = odds ratio; CI = confidence interval.
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out that their male partners were having new partners and
transmitting HPV to them. However, we noted differences
in risk factors associated with HPV infection between
women aged 25-40 years and women aged 49-65 years.
Number of lifetime sex partners, which may be proxy for
cumulative exposure impact [40], was only found to be as-
sociated with HPV infection in older women. Greater
early exposure to HR-HPV infection and weakened im-
mune response after menopause [41] that led to the re-
emergence of latent HPV infections could cause a second
HPV peak in older women. Gravitt et al. [39] found that
there was a second peak around 50-54 years in women
with five or more sex partners but not in those with less
than four sex partners. Their findings may support that
the second peak could be seen in a more generalized
population with a relatively higher cumulative probability
of HPV infection.
HPV persistence
Another explanation, a greater HPV persistence in older
women, was strongly supported by our data (see Additional
file 1: Figure S1). We found an obvious trend of decreasing
clearance or increasing persistence of HPV with increasing
age. The mechanisms could be: 1) decreased ability to clear
recent infections with age-related immune senescence; 2)
predominance of long-duration prevalent infections in older
women from earlier exposures [33].
Thus, we found that the cause of the second peak in
HPV prevalence may be multi-factorial. Despite of the low
number of sex partners, the rural Chinese women were
usually married at an early age and gave a large number of
births. The lifestyles and economic status of the older
rural Chinese women were also much different from other
populations and younger generations. Their poor nutrition
and sanitary condition may cause a poor immune func-
tion, which may in turn result in a reduced ability to clear
HPV infections and to control/prevent the re-emergence
of latent HPV infections.
Our findings agreed with the previous study conducted
in Guanacaste, Costa Rica, which also found that HPV in-
fections tended to clear more often than acquire, and per-
sistence increased with age [33]. However, unlike the
study in Guanacaste, Costa Rica, we did not observe newly
detected infections declining with age.
Risk factors
We also explored the risk factors for HPV prevalence, in-
cidence and clearance using both univariate and multivari-
ate models. Most of our results were similar to the others
[42,43], however, we failed to find the association between
the number of sex partners in the past 6 months and HPV
prevalence in the multivariate model. This may be ex-
plained by the fact that most of the participants reported
to have no or one sex partners in the past 6 months. To
our knowledge, this may not be entirely accurate as some
women may be reluctant to report their actual behaviors.
Impact for cervical cancer screening
The incidence of HPV16,18, and/or 45 was higher and the
clearance was lower in 55 to 65-year-old women, they are
of the greatest risk of persisting HPV16/18/45 infections,
which cause 75% of cervical cancer worldwide [44].
Women aged 55-65 years may be at the highest risk of
progression to cervical precancer or cancer. However, the
first large-scaled cervical cancer screening program in
rural China launched by Chinese government from 2009
to 2011 using VIA or Pap smear does not cover women
older than 60 years [45]. If further studies show these in-
fections representing significant cancer risk in older
women, expanding screening to older ages should be con-
sidered in the future nationwide program in China.
Limitations
This analysis has some limitations. First of all, conveni-
ence sampling was used in recruiting, the participants
may not be perfectly representative. Second, we only
followed up ~20% of the screen negatives, even with ad-
justment, the estimated incidence and prevalence at
follow-up might differ somewhat from the actual values.
Whereas, we conducted a random sampling to get the list
of screen-negative women, so the bias was minimized.
Third, we did not test for the specific HPV type, so that
we could not get the precise status of HPV incidence or
clearance. Given that multiple infections typically repre-
sent 20-30% of all HR-HPV infections and are often more
common in younger women [46], we likely underesti-
mated both one-year clearance and incidence. However,
we granted the same patterns of clearance and incidence
for HPV16/18/45 infections as the overall HR-HPV infec-
tions, which may reflect a relatively low percentage of
women with co-infections of the three types. We only use
a pooled DNA test for 14 certain and probable HR-HPV
types to generally describe the age-group specific patterns
of HR-HPV, which is relevant to cervical cancer screening
and the risk factors associated.
We used clinical tests for HPV, which may have missed
some lower viral load HPV infections that are not strongly
associated with CIN2+. To address this issue, we con-
ducted an additional analysis by defining HPV positive as
either careHPV or HC2 tested positive to increase the
analytic sensitivity. And we observed similar results.
Another notable limitation was the short follow-up
time. As a consequence, some infections persisted for a
year but would have later cleared, while some infections
that appeared to clear were testing errors and would
have tested positive subsequently. However, based on the
results from a meta-analysis which found the median
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duration of HR-HPV detection was 10.9 months in those
HPV-positive women with normal cytology [47], we be-
lieve that measuring the pattern over a year was a good
surrogate for the longer-term persistence. Previous studies
have shown that one-year HPV persistence can strongly
predict longer-term persistence [17] and CIN2+ [47-49].
Conclusions
Our study observed an increase of HR-HPV prevalence in
older women in rural China. The probable explanations
could be: 1) cohort effect; 2) higher than expected inci-
dence; and/or 3) poorer clearance/greater persistence of
HR-HPV at older ages. Long-term prospective studies
with frequent follow-up intervals by HPV genotyping are
needed to verify the conclusions from this study.
Additional file
Additional file 1: Figure S1. Age group-specific, one-year persistence of
any high-risk HPV, any HPV16, 18, and/or 45 (HPV16/18/45), and high-risk
HPV other than HPV16/18/45. Additional file 1: Figure S1 Symbols: (bold line)
Overall, (dash line) HPV16/18/45, (the dot-dash line with solid diamond)
Other.
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